Neoadjuvant endocrine therapy

DRUG3 trials

Sponsors

Ruijin Hospital, George Washington University, Memorial Sloan Kettering Cancer Center

Conditions

Breast CancerBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIICarcinoma, BreastER+ Breast CancerHER2 Negative Breast CarcinomaHER2-negative Breast Cancer

Phase 2

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

RecruitingNCT06806930

George Washington UniversityBreast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III +1

Start: 2024-10-01End: 2028-10-01Target: 90Updated: 2026-03-03

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

RecruitingNCT07483307

Memorial Sloan Kettering Cancer CenterBreast Cancer, ER+ Breast Cancer, HER2-negative Breast Cancer +2

Start: 2026-03-13End: 2030-03-13Target: 176Updated: 2026-06-04

Phase 3

Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

TerminatedNCT02532400

Ruijin HospitalBreast Cancer

Start: 2016-03-31End: 2019-03-31Updated: 2020-03-11